Gene therapy drugs

Recombinant protein drugs

Ophthalmic drugs

Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical enterprise specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic medications. The company was founded in June 2004 and became one of the first companies to list on the Beijing Stock Exchange in November 2021. Its registered capital is 274.271974 million yuan, and its stock code is 920047. The company is a key high-tech enterprise under the National Torch Program, a Beijing-based scientific research and development institution, the Beijing Naked Plasmid Gene Therapy Drug Engineering Technology Research Center, a Beijing International Science and Technology Cooperation Base, a G20 Innovation-Led Enterprise in the Beijing biomedical industry, and a “Specialized, Fine, Distinctive, and New” small and medium-sized enterprise in Beijing.

The company boasts a highly qualified R&D and management team that has accumulated extensive experience in preclinical research, clinical studies, production and quality management, pharmaceutical plant construction, and drug distribution. The company has established a gene...

Guided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise and making positive contributions to the advancement of China’s pharmaceutical industry and human health.